Free Trial
→ Trump Knows Exactly What He's Doing (From Brownstone Research) (Ad)
NASDAQ:SBFM

Sunshine Biopharma 8/11/2023 Earnings Report

Sunshine Biopharma logo
$1.44 0.00 (0.00%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 05/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Sunshine Biopharma EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sunshine Biopharma Revenue Results

Actual Revenue
$5.56 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sunshine Biopharma Announcement Details

Quarter
Date
8/11/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sunshine Biopharma's next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Conference Call Resources

Sunshine Biopharma Earnings Headlines

Sunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
May 6, 2025 | finanznachrichten.de
Sunshine Biopharma launches Everolimus in Canada
April 22, 2025 | markets.businessinsider.com
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
May 30, 2025 | Brownstone Research (Ad)
This Pharma Stock Is Gaining Major Steam Ahead Of Opening Bell
April 2, 2025 | msn.com
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
April 2, 2025 | benzinga.com
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
April 2, 2025 | finance.yahoo.com
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM), a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

View Sunshine Biopharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles